Cargando…

Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis

BACKGROUND: The long-term consequences of unsuccessful interferon-α based hepatitis C treatment on liver disease progression and survival have not been fully explored. METHODS AND FINDINGS: We performed retrospective analyses to assess long-term clinical outcomes among treated and untreated patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozen, Myrna L., Ryan, James C., Shen, Hui, Lerrigo, Robert, Yee, Russell M., Sheen, Edward, Wu, Richard, Monto, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636226/
https://www.ncbi.nlm.nih.gov/pubmed/23637856
http://dx.doi.org/10.1371/journal.pone.0061568
_version_ 1782267295440044032
author Cozen, Myrna L.
Ryan, James C.
Shen, Hui
Lerrigo, Robert
Yee, Russell M.
Sheen, Edward
Wu, Richard
Monto, Alexander
author_facet Cozen, Myrna L.
Ryan, James C.
Shen, Hui
Lerrigo, Robert
Yee, Russell M.
Sheen, Edward
Wu, Richard
Monto, Alexander
author_sort Cozen, Myrna L.
collection PubMed
description BACKGROUND: The long-term consequences of unsuccessful interferon-α based hepatitis C treatment on liver disease progression and survival have not been fully explored. METHODS AND FINDINGS: We performed retrospective analyses to assess long-term clinical outcomes among treated and untreated patients with hepatitis C virus in two independent cohorts from a United States Veterans Affairs Medical Center and a University Teaching Hospital. Eligible patients underwent liver biopsy during consideration for interferon-α based treatment between 1992 and 2007. They were assessed for the probability of developing cirrhosis and of dying during follow-up using Cox proportional hazards models, stratified by pretreatment liver fibrosis stage and adjusted for known risk factors for cirrhosis and characteristics affecting treatment selection. The major predictor was a time-dependent covariate for treatment outcome among four patient groups: 1) patients with sustained virological response to treatment; 2) treatment relapsers; 3) treatment nonresponders; and 4) never treated patients. Treatment nonresponders in both cohorts had a statistically significantly increased hazard of cirrhosis compared to never treated patients, as stratified by pretreatment liver fibrosis stage and adjusted for clinical and psychosocial risk factors that disproportionately affect patients who were ineligible for treatment (Veterans Affairs HR = 2.35, CI 1.18–4.69, mean follow-up 10 years, and University Hospital HR = 5.90, CI 1.50–23.24, mean follow-up 7.7 years). Despite their increased risk for liver disease progression, the overall survival of nonresponders in both cohorts was not significantly different from that of never treated patients. CONCLUSION: These unexpected findings suggest that patients who receive interferon-α based therapies but fail to clear the hepatitis C virus may have an increased hazard of cirrhosis compared to untreated patients.
format Online
Article
Text
id pubmed-3636226
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36362262013-05-01 Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis Cozen, Myrna L. Ryan, James C. Shen, Hui Lerrigo, Robert Yee, Russell M. Sheen, Edward Wu, Richard Monto, Alexander PLoS One Research Article BACKGROUND: The long-term consequences of unsuccessful interferon-α based hepatitis C treatment on liver disease progression and survival have not been fully explored. METHODS AND FINDINGS: We performed retrospective analyses to assess long-term clinical outcomes among treated and untreated patients with hepatitis C virus in two independent cohorts from a United States Veterans Affairs Medical Center and a University Teaching Hospital. Eligible patients underwent liver biopsy during consideration for interferon-α based treatment between 1992 and 2007. They were assessed for the probability of developing cirrhosis and of dying during follow-up using Cox proportional hazards models, stratified by pretreatment liver fibrosis stage and adjusted for known risk factors for cirrhosis and characteristics affecting treatment selection. The major predictor was a time-dependent covariate for treatment outcome among four patient groups: 1) patients with sustained virological response to treatment; 2) treatment relapsers; 3) treatment nonresponders; and 4) never treated patients. Treatment nonresponders in both cohorts had a statistically significantly increased hazard of cirrhosis compared to never treated patients, as stratified by pretreatment liver fibrosis stage and adjusted for clinical and psychosocial risk factors that disproportionately affect patients who were ineligible for treatment (Veterans Affairs HR = 2.35, CI 1.18–4.69, mean follow-up 10 years, and University Hospital HR = 5.90, CI 1.50–23.24, mean follow-up 7.7 years). Despite their increased risk for liver disease progression, the overall survival of nonresponders in both cohorts was not significantly different from that of never treated patients. CONCLUSION: These unexpected findings suggest that patients who receive interferon-α based therapies but fail to clear the hepatitis C virus may have an increased hazard of cirrhosis compared to untreated patients. Public Library of Science 2013-04-25 /pmc/articles/PMC3636226/ /pubmed/23637856 http://dx.doi.org/10.1371/journal.pone.0061568 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Cozen, Myrna L.
Ryan, James C.
Shen, Hui
Lerrigo, Robert
Yee, Russell M.
Sheen, Edward
Wu, Richard
Monto, Alexander
Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis
title Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis
title_full Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis
title_fullStr Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis
title_full_unstemmed Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis
title_short Nonresponse to Interferon-α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis
title_sort nonresponse to interferon-α based treatment for chronic hepatitis c infection is associated with increased hazard of cirrhosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636226/
https://www.ncbi.nlm.nih.gov/pubmed/23637856
http://dx.doi.org/10.1371/journal.pone.0061568
work_keys_str_mv AT cozenmyrnal nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT ryanjamesc nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT shenhui nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT lerrigorobert nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT yeerussellm nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT sheenedward nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT wurichard nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis
AT montoalexander nonresponsetointerferonabasedtreatmentforchronichepatitiscinfectionisassociatedwithincreasedhazardofcirrhosis